Qlife Holding AB (publ), a med-tech company, manufactures and sells in-vitro diagnostic analyzers and reagents in Sweden. The company offers Egoo.Health Platform, a product platform that enables advanced biomarker testing, consisting of a small device, disposable capsules, and the supplementing software. Qlife Holding AB (publ) was incorporated in 2019 and is based in Gothenburg, Sweden.…
Nordic outperformance widens, US biotech retreats sharply
Qlife Holding (STO: QLIFE) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 2 employees.
The shares were at 0.8810 SEK on 20 November 2026, down 57.0% over 52 weeks. Its 52-week range is 0.6510 SEK to 3.800 SEK: the price is 76.8% below the high and 35.3% above the low.
Its market capitalisation is 25.44M SEK.
Qlife Holding reports return on equity of 273.8%.
Its debt exceeds its cash by 6.27M SEK. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health.